Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Livzon Pharmaceutical Group ( (HK:1513) ).
Livzon Pharmaceutical Group has announced that its Recombinant anti-human IL-17A/F Humanized Monoclonal Antibody Injection, developed in collaboration with Beijing Kanova Biopharmaceutical, has achieved the primary endpoint in a phase III clinical trial for moderate-to-severe plaque psoriasis. The trial results demonstrated that the drug, LZM012, is non-inferior and even superior to the control drug secukinumab, with a faster onset of action and sustained benefits over time. The company is advancing towards market launch by submitting an application to the National Medical Products Administration, which could enhance its positioning in the psoriasis treatment market.
The most recent analyst rating on (HK:1513) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group is a company involved in the pharmaceutical industry, focusing on the development and production of therapeutic biological products. Its primary products include humanized monoclonal antibody injections, with a market focus on innovative treatments for conditions like psoriasis.
YTD Price Performance: 42.04%
Average Trading Volume: 1,889,324
Technical Sentiment Signal: Buy
Current Market Cap: HK$38.75B
For a thorough assessment of 1513 stock, go to TipRanks’ Stock Analysis page.